Piracetam for Treatment of Cocaine Addiction, Phase II - 4

This study has been completed.

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) University of Pennsylvania
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000199

Purpose

The purpose of this study is to follow patients in Phase I of an inpatient study in an eight week open label assessment of piracetam in an outpatient treatment program.

Condition	Intervention	Phase
Cocaine-Related Disorders	Drug: Piracetam	Phase I

Drug Information available for: 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))- Cocaine hydrochloride Piracetam

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Piracetam for Treatment of Cocaine Addiction, Phase II

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Drug use
Adverse effects
Clinical status

Estimated Enrollment:

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000199

Locations

United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104 6178

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

University of Pennsylvania

Investigators

Principal Investigator:

Kyle Kampman, M.D.

University of Pennsylvania

More Information

Study ID Numbers:	NIDA-00238-4, K02-00238-4
Study First Received:	September 20, 1999
Last Updated:	November 24, 2008
ClinicalTrials.gov Identifier:	NCT00000199
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Cocaine-Related Disorders
Behavior, Addictive
Mental Disorders
Substance-Related Disorders

Piracetam
Disorders of Environmental Origin
Cocaine

Additional relevant MeSH terms:

Nootropic Agents
Therapeutic Uses
Physiological Effects of Drugs
Central Nervous System Agents

Protective Agents
Neuroprotective Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 15, 2009